Gilde Healthcare

Gilde Healthcare Partners B.V. is a private equity and venture capital firm based in Utrecht, Netherlands, with additional offices in Cambridge, Massachusetts, and Frankfurt am Main, Germany. Established in 2000, Gilde specializes in management buy-outs and growth capital investments in the healthcare sector, targeting companies in healthcare technology, medtech, diagnostics, digital health, therapeutics, and healthcare services. The firm manages over €800 million in assets and seeks to invest between €1 million and €35 million in businesses with enterprise values up to €150 million. Gilde focuses on both clinical and commercial stage companies, particularly in biopharma, diagnostics, and medical devices, with an emphasis on cardiology, oncology, and women's health. The firm prefers to take majority and minority stakes and aims to lead investments while securing a seat on the board of its portfolio companies. Gilde Healthcare primarily invests in the United States and Europe, particularly in the Benelux region and the DACH area. Exits are typically achieved through IPOs, sales to strategic buyers, or private placements.

Susana Amorim

Senior Associate Healthtech Venture&Growth

Dirkjan Beugelsdijk

CFO

Josephine Bogaerts

Associate Private Equity

Fabian Braemisch

Partner

Hugo de Bruin

Partner

Janke Dittmer

General Partner

Arthur Franken

Founding Member & General Partner - Healthtech/Therapeutics, Venture & Growth

Jasper van Gorp

Managing Partner

Edwin de Graaf

Co-Founder & Managing Partner

Edward Hanlon

Associate Healthtech Venture&Growth

Joep Heldens

Associate Private Equity

Sanne de Jongh

Investment Manager Therapeutics Venture&Growth

Redmar Koene

Investment Manager

Job Komen

Partner

Stefan Luzi Ph.D

Partner

Pieter van der Meer

Managing Partner

Joep Muijrers

General Partner

Rafael Natanek

Partner Private Equity

Geoff Pardo

General Partner - Healthtech, Venture & Growth

Geoffrey B. Pardo

Partner and General Partner

Marc Olivier Perret

Managing Partner

Julian Primer

Analyst Private Equity

Matteo Racca

Partner

Tom Robbenhaar

Partner

Boyd Rutten

Investment Director

Georg von Schwarzkopf

Investment Manager

Dan Secor

Associate Healthtech Venture&Growth

Robert Stein

Partner

Matthew Vessa

Vice President

Stephan Wachtveitl

Senior Associate

Henry Zubaida

Investment Manager

Past deals in Copenhagen

ADCendo

Series A in 2021
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.